Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12707808 | 0.96 | FFAR1 (0.57) | FFAR1PPARGGABRA1GABRG2GABRB3 | |
| SCHEMBL29873861 | 0.86 | FFAR1 (0.55) | FFAR1PPARG | |
| SCHEMBL183440 | 0.86 | FFAR1 (0.48) | FFAR1PPARGGABRA1GABRG2GABRB3 | |
| SCHEMBL5651128 | 0.82 | FFAR1 (0.70) | FFAR1PPARG | |
| SCHEMBL1584822 | 0.81 | FFAR1 (0.77) | FFAR1PPARGGABRA1GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL4055966 | 0.80 | FFAR1 (0.68) | FFAR1PPARG | |
| SCHEMBL5192317 | 0.80 | NOS2 (0.57) | — | |
| SCHEMBL6883859 | 0.79 | FFAR1 (0.56) | FFAR1PPARG | |
| SCHEMBL8095933 | 0.78 | MEN1 (0.54) | — | |
| SCHEMBL6211340 | 0.78 | MEN1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241082-A1 | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease | FLECKENSTEIN ANNETTE E | 2006-10-26 | — | — | US | disclosed |
| WO-2004026258-A2 | MODULATING VESICULAR MONOAMINE TRANSPORTER TRAFFICKING AND FUNCTION: A NOVEL APPROACH FOR THE TREATMENT OF PARKINSON’S DISEASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241082-A1 | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease | SLC18A2, SLC18A3, SLC6A3 | FFAR1 1734/4885PPARG 1874/4885GABRA1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.